| Literature DB >> 34100395 |
Sudhir Chandra Sarangi1, Bikash Medhi2, Ajay Prakash2, Jai Prakash3, Yogendra K Gupta4.
Abstract
OBJECTIVES: The National Formulary of India (NFI), a ready reckoner for medicines among healthcare-professionals aims for promoting rational drug use. This needs periodic update based on evidence-based medicines and suggestions from end-users. This study assessed the level of awareness among health-care professionals and sought suggestions for enhancement of utility/content of NFI.Entities:
Keywords: Healthcare professionals; national formulary of India; pan-India survey; practical usefulness; rational use of drugs
Mesh:
Year: 2021 PMID: 34100395 PMCID: PMC8265414 DOI: 10.4103/ijp.ijp_353_21
Source DB: PubMed Journal: Indian J Pharmacol ISSN: 0253-7613 Impact factor: 1.200
Participants’ response to the questions in the survey regarding enhancement of utility of NFI
| Total response ( | |
|---|---|
| 1. While practicing, which of the following source you consult for ready information about medicines.* | 452 (98.0) |
| a. CIMS alone or with other sources (MIMS, IDR, WHO formulary, NFI, BNF) | 251 (55.5) |
| b. NFI alone or with other sources | 214 (47.3) |
| c. NFI alone | 55 (12.2) |
| 2. Do you think NFI will give balanced unbiased information about medicines? | 457 (99.1) |
| a. Yes | 376 (82.3) |
| b. No | 12 (2.6) |
| c. No comment | 69 (15.1) |
| 3. In your opinion, use of NFI promotes rational use of drug | 457 (99.1) |
| a. Yes, it does | 313 (68.5) |
| b. No, it does not | 5 (1.1) |
| c. Need to be assessed | 112 (24.5) |
| d. No comment | 27 (5.9) |
| 4. NFI is published by | 45197.8) |
| a. IPA | 20 (4.4) |
| b. IPC | 419 (92.9) |
| c. OPPI | 8 (1.8) |
| d. MCI | 4 (0.9) |
| 5. How would you like to access NFI? | 459 (99.6) |
| a. Have a personal printed version of NFI (alone) | 122 (26.6) |
| b. Have a personal printed version of NFI (alone or with other) | 209 (45.5) |
| c. Will consult NFI printed version in library (alone) | 21 (4.6) |
| d. Will consult NFI printed version in library (alone or with other) | 47 (10.2) |
| e. Will prefer free downloadable App (alone) | 154 (33.5) |
| f. Will prefer free downloadable App (alone or with other) | 260 (56.6) |
| g. Will like to subscribe upgradable version of NFI App (alone) | 36 (7.8) |
| h. Will like to subscribe upgradable version of NFI App (alone or with other) | 94 (20.5) |
| 6. To what extent NFI is helpful in your clinical practice? | 459 (99.6) |
| a. Very useful | 207 (45.1) |
| b. Useful to some extent | 145 (31.6) |
| c. Not useful | 2 (0.4) |
| d. Never used NFI | 102 (22.2) |
| 7. National formulary of India is | 457 (99.1) |
| a. A reference document for clinical practice | 315 (68.9) |
| b. A book mentioning the chemical formula of drugs | 102 (22.3) |
| c. A document with treatment regimens for common diseases | 152 (33.3) |
| d. A document about the newly launched drugs in India | 94 (20.6) |
| 8. NFI can be used for the following purposes | 455 (98.7) |
| a. Legal document for safeguard of health care provider | 131 (28.7) |
| b. Promoting material by pharmaceutical company | 29 (6.37) |
| c. Reference document during practice for medical professionals | 413 (90.8) |
| d. Reference material for consumer/patients for self-medication | 36 (7.9) |
| 9. NFI provide information about the following | 456 (98.9) |
| a. Drugs commonly used and their indications | 438 (96.0) |
| b. Common disease symptomatology | 31 (6.8) |
| c. Diagnostic investigation procedures for common diseases | 25 (5.5) |
| d. Guidance for conducting clinical research | 33 (7.2) |
| 10. Practitioner can find following information about medicines in NFI | 457 (99.1) |
| a. Clinical indications | 279 (61.0) |
| b. Dose, dosage forms and strengths | 418 (91.5) |
| c. Brands of drugs available in market | 156 (34.4) |
| d. Contraindications and precautions | 261 (57.1) |
| e. Right options (clinical indications; dose, dosage forms and strengths; contraindications and precautions) | 116 (25.4) |
| 11. NFI serves the following purpose | 456 (98.9) |
| a. Promoting more popular drugs | 30 (6.6) |
| b. Rational use of drugs | 421 (92.3) |
| c. Guideline for disease management | 109 (23.9) |
| d. Regulatory approval status of drugs | 126 (27.6) |
| 12. Medicines mentioned in NFI are aligned with | 454 (98.5) |
| a. Essential medicines list of WHO | 179 (39.4) |
| b. National list of essential medicines of India | 379 (83.5) |
| c. Standard treatment workflow | 72 (15.9) |
| d. High selling drugs in the market | 11 (2.4) |
| 13. NFI contain monographs for the following | 452 (98.0) |
| a. Medicines | 431 (95.3) |
| b. Diagnostic agents | 50 (11.1) |
| c. Health and hygienic product | 57 (12.6) |
| d. Medical devices | 46 (10.2) |
| 14. NFI should also provide information on the following | 449 (97.4) |
| a. Disposal of expired pharmaceutical products | 174 (38.7) |
| b. Drugs for basic medical emergencies | 320 (71.3) |
| c. Drug procurement practices in hospitals | 160 (35.6) |
| d. Pharmaceutical price control policy | 163 (36.3) |
| 15. Following information will make NFI more useful* | 446 (96.7) |
| a. Drugs used for doping | 98 (22.0) |
| b. Common drug interactions | 395 (88.6) |
| c. Normal values of electrolytes | 78 (17.5) |
| d. Nomogram for drug titration in poor LFT and KFT | 259 (58.1) |
| e. Drugs with potential teratogenicity | 263 (59.0) |
| 16. National Formulary of India would improve the quality of care within the health care delivery system | 452 (98.0) |
| a. Fully agree | 285 (63.0) |
| b. Agree to some extent | 136 (30.1) |
| c. Not agree at all | 1 (0.2) |
| d. Cannot comment | 30 (6.6) |
| 17. Following can be added to drug monograph to increase utility of NFI?* | 444 (96.3) |
| a. Common brand name of drugs available in market | 110 (24.8) |
| b. Price range of available drug brands in the market | 100 (22.5) |
| 18. Will you suggest/recommend your colleagues to use NFI in their clinical practice? | 444 (96.3) |
| a. Yes, because it will promote safe use of medicines | 432 (97.3) |
| b. Yes, because it will improve the income of doctor | 6 (1.3) |
| c. No, it is very cumbersome to use it | 6 (1.3) |
| 19. Will you like to attend 1 day CME organized by NFI? | 449 (97.4) |
| a. Yes | 405 (90.2) |
| b. No | 44 (9.8) |
*Open-ended questions along with choices. CIMS=Current index of medical specialties, MIMS=Monthly index of medical specialties, IDR=Indian drug review, KFT=Kidney function test, LFT=Liver function test, CME=Continuing medical education, WHO=World Health Organization, NFI=National formulary of India, BNF=British national formulary, IPA=Indian pharmaceutical alliance, IPC=Indian pharmacopoeia commission, OPPI=Organization of pharmaceutical producer of India, MCI=Medical council of India
Recommendations by the respondents regarding enhancement of utility of National formulary of India
| Reference question | Responses mentioned in question | Other responses | Number of respondents |
|---|---|---|---|
| Question 1: While practicing, which of the following source you consult for ready information about medicines | CIMS, MIMS, IDR, WHO formulary, NFI, BNF | Internet (1 mg.com, centerwatch.com, drugs.com, Medscape, UpToDate, Google, Lexicomp, Micromedex, Docguide, PubMed) | 44 |
| Textbooks | 13 | ||
| Senior doctors | 2 | ||
| Question 15: Following information will make NFI more useful | Drugs used for doping, common drug interactions, normal values of electrolytes, nomogram for drug titration in poor LFT and KFT, Drugs with potential teratogenicity | Antidotes | 2 |
| Drugs dosing in specific population-pediatric, pregnancy, lactation | 4 | ||
| Approximate cost, maximum price of drugs under NPPA | 2 | ||
| Drugs with abusive potentials | 2 | ||
| Suitable substitute drugs in case of ADR | 1 | ||
| Off label use of drugs | 1 | ||
| Orphan drugs | 1 | ||
| Drug alerts, labels | 1 | ||
| Standard treatment guidelines | 1 | ||
| Treatment regimen for common diseases | 1 | ||
| Biologics and biosimilars, nutraceuticals | 1 | ||
| Question 17: Following can be added to drug monograph to increase utility of NFI? | Common brand name of drugs available in market, price range of available drug brands in the market | Source/places of availability of generic medicines | 3 |
| Pharmaceutical price control policy, maximum price under NPPA | 2 | ||
| Most cost effective brands | 1 | ||
| Disposal of expired drugs | 1 | ||
| Off label use of drugs | 1 | ||
| Newer drugs approved and drugs in clinical trial | 1 | ||
| Synopsis of clinical trials | 1 | ||
| Question 20: Any other comment on national formulary of India | It should be freely available/easily accessible/available as mobile app/offline app/PDF/soft copy | 29 | |
| A copy should be made available in all hospitals for reference purpose | 1 | ||
| Precautions in special groups like geriatric | 1 | ||
| CME on NFI should be online and to occur every year with topics like new drugs approval, drug resistance, rational use of drugs, drug interaction | 1 | ||
| Drug resistance and drug interactions in Indian population | 1 | ||
| Awareness for its use is needed | 1 | ||
| Updated at fixed interval | 1 | ||
| Step wise treatment algorithm for common diseases | 1 | ||
| Management of common and emergency conditions | 1 | ||
| New drugs information to be available in NFI | 1 | ||
| Types of poison and their treatment | 1 | ||
| Inclusion in MBBS curriculum is a must | 1 |
CIMS=Current index of medical specialties, MIMS=Monthly index of medical specialties, IDR=Indian drug review, KFT=Kidney function test, LFT=Liver function test, NPPA=National pharmaceutical pricing authority, ADR=Adverse drug reaction, CME=Continuing medical education, WHO=World Health Organization